마우스의 당뇨병에 대한 과립세포자극인자와 단핵 세포를 이용한 면역 치료
Immunotherapy of Diabetes Mellitus in the Mouse by the Injection of Granulocyte cell Stimulating Factor and Mononuclear cells
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
다양한 면역 치료법을 통한 질병의 치료가 의학계에서 지속적으로 연구되고 있다. 본 연구에서는 면역치료법 중 과립세포자극인자(granulocyte cell stimulating factor, GCSF) 투여를 통한 면역 활성화와, 단핵구 이식을 통한 당뇨 모델의 치료 효과를 보고자 하였다. 당뇨 모델은 스트렙토조토신(streptozotocin, STZ)을 투여한 후 혈당 및 행동의 변화를 확인하였다. 이후 한 군은 단핵구를 이식하고, 다른 한 군은GCSF를 투여한 뒤 혈액을 분석하고, 합병증과 치료 효과를 보기 위해 간과 신장도 관찰하였다. 그 결과STZ군이 전체적으로 행동 능력이 떨어졌지만 단핵구와 GCSF의 투여로 torso twist와 escape test 결과가향상되어 단기적인 치료효과가 있는 것으로 나타났다. 이 연구를 통해 단핵구와 GCSF의 당뇨병에 대한 단기 치료 여부를 확인할 수 있었으나 이후 장기적 치료 여부를 추가로 확인할 필요가 있다. 이러한 결과는면역계를 활성화하는 면역치료가 당뇨의 합병증 예방을 하는데 활용될 수 있다는 가능성을 제시한 데 의의가 있다.
Abstract
Treatment of diseases using immunotherapy is an active field in medical research. In this research, we aimed to examine the role of granulocyte cell stimulating factor (GCSF) injection and mononuclear cell (MNC) transplantation in treating diabetes mellitus(DM) induced by streptozotocin in mouse. Behavior experiments and blood analyses were performed on DM induced groups treated with either GCSF or MNC. In addition, liver and kidney examinations were made to compare toxicity at the organ level. Treatment of either GCSF or MNC improved scores in behavior experiments but had no significant effect on blood cell counts within short term periods. Thus, experiments on longer time scales are required for GCSF to activate hematosis. Overall, the results show possibilities of using immunotherapy in treating complications developed by diabetes.
참고문헌 (14)
- Di Campli, Cristiana, "Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure", Digestive and Liver Disease, 39(12), pp.1071~1076 (2007)
- Gaia, S., "Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease", Journal of hepatology, 45(1), pp.13~19 (2006)
- Huang, P., "Autologous transplantation of granulocyte colony–stimulating factor–mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes", Diabetes care, 28(9), pp.2155~2160 (2005)
- Hussain, M. A., "Stem-cell therapy for diabetes mellitus", The Lancet, 364(9429), pp.203~205 (2004)
- Kumar, A. A., "Autologous bone marrow derived mononuclear cell therapy for spinal cord injury : a phase I", II clinical safety and primary efficacy data, 2009, pp.7(4), 241~248
- Lindvall, O., "Stem cell therapy for human neurodegenerative disorders–how to make it work" (2004)
- Petit, I., "G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4", Nature immunology, 3(7), pp.687~694 (2002)
- Segers, V. F., "Stem-cell therapy for cardiac disease", Nature, 451(7181), pp.937~942 (2008)
- Strauer, B. E., "Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans", Circulation, 106(15), pp.1913~1918 (2002)
- Van Huyen, J. P. D., "Bone marrow-derived mononuclear cell therapy induces distal angiogenesis after local injection in critical leg ischemia", Modern Pathology, 21(7), pp.837~846 (2008)
- Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia : report of a WHO, "IDF consultation", WHO, World Health Organization press, pp.2006, ~
- Willfort, A., "Treatment of drug-induced agranulocytosis with recombinant granulocyte colony-stimulating factor(rh G-CSF)", Annals of hematology, 66(5), pp.241~244 (1993)
- Rahavi H, "Adipose tissue-derived mesenchymal stem cells exert in vitro immunomodulatory and Beta cell protective functions in streptozotocin-induced diabetic mice model", J Diabetes Res, pp.878535~ (2015)
- 오승현, "당뇨병-고지혈증 모델동물의 개발", 환경독성보건학회지, 19(3), pp.287~294 (2004), 환경독성보건학회